88 related articles for article (PubMed ID: 11002427)
1. Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma.
Fenstermaker RA; Ciesielski MJ
Oncogene; 2000 Sep; 19(39):4542-8. PubMed ID: 11002427
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function.
Ciesielski MJ; Fenstermaker RA
Oncogene; 2000 Feb; 19(6):810-20. PubMed ID: 10698499
[TBL] [Abstract][Full Text] [Related]
3. Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells.
Fenstermaker RA; Ciesielski MJ; Castiglia GJ
Oncogene; 1998 Jul; 16(26):3435-43. PubMed ID: 9692551
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
6. Localization of aberrant messenger RNA of epidermal growth factor receptor (EGFR) in malignant glioma.
Tsugu A; Kijima H; Yamazaki H; Ohnishi Y; Takamiya Y; Abe Y; Ueyama Y; Sato O; Tamaoki N; Nakamura M
Anticancer Res; 1997; 17(3C):2225-32. PubMed ID: 9216693
[TBL] [Abstract][Full Text] [Related]
7. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
Bremm A; Walch A; Fuchs M; Mages J; Duyster J; Keller G; Hermannstädter C; Becker KF; Rauser S; Langer R; von Weyhern CH; Höfler H; Luber B
Cancer Res; 2008 Feb; 68(3):707-14. PubMed ID: 18245470
[TBL] [Abstract][Full Text] [Related]
8. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.
Arjona D; Bello MJ; Alonso ME; Aminoso C; Isla A; De Campos JM; Sarasa JL; Gutierrez M; Villalobo A; Rey JA
Neuropathol Appl Neurobiol; 2005 Aug; 31(4):384-94. PubMed ID: 16008822
[TBL] [Abstract][Full Text] [Related]
10. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
11. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.
Luwor RB; Zhu HJ; Walker F; Vitali AA; Perera RM; Burgess AW; Scott AM; Johns TG
Oncogene; 2004 Aug; 23(36):6095-104. PubMed ID: 15221011
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
[TBL] [Abstract][Full Text] [Related]
13. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.
Xu K; Shu HK
Cancer Res; 2007 Jul; 67(13):6121-9. PubMed ID: 17616668
[TBL] [Abstract][Full Text] [Related]
14. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
[TBL] [Abstract][Full Text] [Related]
15. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
16. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
Yang B; Chen J; Zhang X; Cao J
Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
[TBL] [Abstract][Full Text] [Related]
17. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
[TBL] [Abstract][Full Text] [Related]
18. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
20. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
